Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 7/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929186 | 1.00 | DNPH1 (0.48) | DNPH1TK2TK1LMNATHRB | |
| SCHEMBL14928925 | 0.94 | TK2 (0.42) | DNPH1TK2TK1LMNATHRB | |
| SCHEMBL14946210 | 0.94 | TK2 (0.42) | DNPH1TK2TK1LMNATHRB | |
| SCHEMBL14928974 | 0.91 | TK2 (0.40) | DNPH1TK2TK1LMNATHRB | |
| SCHEMBL18561514 | 0.91 | TK2 (0.40) | DNPH1TK2TK1LMNATHRB | |
| SCHEMBL14928922 | 0.87 | TK2 (0.53) | TK2TK1LMNATYMP | |
| SCHEMBL14928930 | 0.87 | TK2 (0.53) | TK2TK1LMNATYMP | |
| SCHEMBL16805355 | 0.86 | PYGM (0.50) | TK2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL14929102 | 0.86 | PYGM (0.50) | TK2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL16340827 | 0.84 | TK2 (0.57) | DNPH1TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | DNPH1 467/4885TK2 151/4885TK1 198/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | DNPH1 467/4885TK2 151/4885TK1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.